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Abstract
Purpose: Currently, no outcome measures are clinically vali-
dated and accepted as clinical endpoints by regulatory 
agencies for drug development in intermediate age-related 
macular degeneration (iAMD). The MACUSTAR Consortium, 
a public-private research group funded by the European In-
novative Medicines Initiative intends to close this gap. Pro-
cedures: Development of study protocol and statistical anal-
ysis plan including predictive modelling of multimodal end-
points based on a review of the literature and expert 
consensus. Results: This observational study consists of a 
cross-sectional and a longitudinal part. Functional outcome 
measures assessed under low contrast and low luminance 
have the potential to detect progression of visual deficit 
within iAMD and to late AMD. Structural outcome measures 
will be multimodal and investigate topographical relation-
ships with function. Current patient-reported outcome mea-
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sures (PROMs) are not acceptable to regulators and may not 
capture the functional deficit specific to iAMD with needed 
precision, justifying development of novel PROMs for iAMD. 
The total sample size will be n = 750, consisting mainly of 
subjects with iAMD (n = 600). Conclusions: As clinical end-
points currently accepted by regulators cannot detect func-
tional loss or patient-relevant impact in iAMD, we will clini-
cally validate novel candidate endpoints for iAMD.
© 2018 S. Karger AG, Basel
Introduction
Age-related macular degeneration (AMD) affects al-
most 30% of the older population and progresses slowly 
from early AMD to intermediate AMD (iAMD) and ulti-
mately late-stage AMD with severe and frequently irre-
versible visual loss over a decade [1]. Population aging 
will lead to a considerable increase in AMD prevalence. 
Today, late-stage AMD is the leading cause of blindness 
among the elderly in industrialized countries and affects 
more than 2.5 million patients in the EU [2–4] resulting 
in direct annual costs of over 2 billion Euros [5]. 
In order to reduce the significant burden of late AMD, 
novel interventions that stop or delay progression from 
iAMD to late AMD will need to be developed [6]. This 
has been highlighted by the number of failed studies to 
prevent the progression of geographic atrophy (GA) 
with different approaches such as inhibiting comple-
ment and visual cycle modulators. Parallels with Alz-
heimer’s disease have been noted, where it is felt that part 
of the failure of clinical trials (CTs) to date has been the 
onset of treatment too late in the disease process [7, 8]. 
For CT clinical endpoints validated and accepted by reg-
ulatory agencies, health technology assessment (HTA) 
bodies, and payers are needed. Currently, these do not 
exist for iAMD CTs. The currently accepted endpoints 
like high-contrast, high-luminance best-corrected visual 
acuity (BCVA), are not appropriately reflecting the vi-
sual deficit in iAMD or only after progression to late 
AMD, which may require an observation period of up to 
several years. Therefore, BCVA is not an adequate end-
point for iAMD CTs.
Still, there is good evidence indicating that patients 
with iAMD experience impairment of visual function, yet 
it is unknown to what extent this impacts the patients’ life 
or how it can reliably be measured and quantified [9–11]. 
It is also not well known which the specific risk factors in 
the population of iAMD patients are to identify those 
with more rapid progression to late stages of the disease. 
Therefore, the successful development of iAMD inter-
ventions requires validated functional, morphological, 
and patient-reported endpoints for CTs which are clini-
cally meaningful and accepted by regulatory agencies. In 
addition, functional decline in iAMD and specific risk 
factors for iAMD progression to late AMD need to be bet-
ter characterized to inform and improve conduct of fu-
ture iAMD CTs.
Against this background, the major objective of the 
MACUSTAR consortium is to develop novel clinical end-
points for CTs with a regulatory and patient access inten-
tion in the area of functional, structural, and patient-re-
ported outcome measures in patients with iAMD. 
For this objective, it is not sufficient to test different 
endpoint categories in isolation, e.g. optimizing an imag-
ing parameter without providing functional data to dem-
onstrate that progression of disease shown by images is 
also reflected in functional measures and/or measures of 
patient-reported health. Specifically, this holistic and in-
tegrative approach for prospectively looking for correla-
tion of candidate endpoints in one validation study is one 
of the unique strengths of the MACUSTAR project.
Using this approach, MACUSTAR will also character-
ize visual impairment in iAMD and its progression, as 
well as identify risk factors for progression to late-stage 
AMD. Herein, we report the process of selection and op-
timization of candidate outcome measures, protocol de-
velopment, and considerations for statistical analyses for 
the MACUSTAR clinical study which will deliver the 
above-mentioned clinical endpoints.
Materials and Methods
Consortium Structure
The MACUSTAR consortium (online suppl. material; for all 
online suppl. material, see www.karger.com/doi/10.1159/491402) 
was awarded funding by the European Union Innovative Medi-
cines Initiative 2 (IMI2) based on the Call 7 Topic 4 (No. IMI2-
2015-07-04): “Dry Age-Related Macular Degeneration: Develop-
ment of Novel Clinical Endpoints for Clinical Trials with a Regula-
tory and Patient Access Intention.”
The call topic text used the term “dry” AMD, which only sepa-
rates AMD with choroidal neovascularization (CNV) (wet AMD) 
form all other AMD forms (dry AMD). In the MACUSTAR proj-
ect (and as also suggested in the call topic text), the Beckman clas-
sification of AMD will be used as this much better reflects the pro-
gressive nature of AMD [12]. In line with the description of the call 
topic text, the MACUSTAR project will focus on assessment of 
patients with iAMD and the progression of iAMD to late-stage 
AMD (comprising neovascular wet AMD and atrophic AMD or 
GA). Patients with no AMD, early AMD, and neovascular AMD 
will be included in cross-sectional assessments to demonstrate the 
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degree of discrimination of iAMD and its progression to late-stage 
AMD by the candidate endpoints.
IMI2 is the world’s largest public private partnership in life sci-
ences, with the EU providing funding which is matched by the 
European Federation of Pharmaceutical Industries and Associa-
tions (EFPIA) and all projects include academic and industrial 
partners (EFPIA members and associated companies). Research-
ers from academia and industry work actively and jointly on all 
parts of research project. Decision bodies of IMI2 consortia have 
a 1: 1 distribution of academic and industry votes.
To optimally address the research question, the MACUSTAR 
consortium is structured in five work packages (WPs; see online 
suppl. material). These include conduct of the clinical study 
(WP1 – Clinical Trial), functional outcome measures (WP2 – 
Functional Endpoints), patient-reported outcome measures 
(WP3 – Patient-reported Heath and Health economics), structur-
al outcome measure/imaging (WP4 – Anatomical and Imaging 
Endpoints), and project coordination (WP5 – Project Manage-
ment, Communication, and Dissemination). 
Protocol Development
Based on a review of the available literature up to September 
2016 on PubMed as well as expert consensus within the consor-
tium (see list of members) and with regulators, candidate out-
come measures for clinical validation as endpoints were identi-
fied. Outcome measures were chosen to be included into the MA-
CUSTAR clinical study if there were data supporting their use in 
iAMD, sufficient evidence to support adequate quality of the 
measurement obtained, testing could be standardized across 
multiple sites, and test burden would be compatible with a mul-
tisite setting and repetition of measurements for a follow-up of 
typically 2–3 years.
Study design was chosen to allow for the most comprehensive 
evaluation of chosen outcome measures, including assessments of 
reliability, responsiveness to change over time, structure-function 
correlation, and patient relevance. 
Interaction with Regulators and HTA Bodies
The MACUSTAR consortium targets validation and accep-
tance of candidate endpoints by regulatory and HTA bodies. As 
such, it is central to early on align the validation strategy. Specifi-
cally, the design and analysis approach for clinical data acquisition 
and generation are developed with external input by stakeholders. 
For the MACUSTAR clinical study, feedback was implemented 
from patient organizations such as Retina International. In addi-
tion, the consortium initiated an official scientific advice proce-
dure on biomarker qualification from regulatory agencies and 
HTA bodies early on in 2016/2017 before the active funding phase 
of the project. The scientific advice procedure including EMA, US 
FDA, and NICE was completed in April 2017 with a letter of sup-
port to the project issued by EMA (www.ema.europa.eu).
Discussions and feedback on general approaches for biomark-
er qualification in iAMD, on how to best correlate the different 
endpoint categories, and on the clinical study design and statistical 
analyses were integrated into the subsequent protocol develop-
ment, sample size calculations, and project planning.
Two further follow-on joint scientific advices with EMA, US 
FDA, and NICE are targeted for biomarker qualification with (1) 
Screening Baseline Validation M6 M12 M18 M24 M30 M36
Day
–28 to –1 Day 0 14 days ±28 days ±28 days ±28 days ±28 days ±28 days ±28 days
No abnormalities or
normal aging changes
n = 50
Early AMD
n = 50
Early AMD
n = 50
Early AMD
n = 50
Early AMD
n = 50
Late AMD
n = 50
Cross-sectional analysis (by AMD status and across AMD status)
• Technical evaluation of methods/reliability of methods for assessment of clinical endpoints
• Correlation of candidate endpoints with measures of patient-reported health/quality of life
• Correlation of candidate endpoints with AMD severity stage (according to the Beckman classification)
Longitudinal analysis
• Longitudinal follow-up of endpoint candidates in primary target population
• Predictive power of endpoint candidates for progression of vision impairment in intermediate AMD and
 progression to late AMD
Intermediate AMD
n = 600 for 3-year follow-up period, subgroup of 150 patients will have additional validation visit (day 7–21)
Fig. 1. Overall structure of the MACUSTAR clinical study.
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a data package from the first cross-sectional part, and (2) a final 
data package from the longitudinal part of the MACUSTAR clini-
cal study (see below) at the end of the funding period.
Terminology Clarifications
All measures developed in this project are referred to as out-
come measures, in lieu of a clinical endpoint, which requires ac-
ceptance by regulatory authorities and payers. 
Results
Study Design
The outcome measures will be assessed in both parts 
of the MACUSTAR clinical study, the cross-sectional and 
the longitudinal part (Fig. 1).
These parts are operationally combined under one 
study protocol for synergies as they include identical as-
sessments, identical functional and imaging devices, 
identical clinical sites and investigators, and for iAMD a 
partially overlapping patient sample (Fig. 1). 
The two parts of the study are:
(1) Cross-sectional part. It consists of a comparative 
analysis of functional, structural, and patient-reported 
outcomes in age-matched subjects with normal ocular 
aging changes only (no AMD), and in patients with early 
AMD, iAMD, and late-stage AMD. For this part, two vis-
its will be analyzed; the baseline visit (day 1) and a short-
term follow-up visit (21 ± 7 days). The total number of 
patients in the cross-sectional part is 300. The data gener-
ated will be used for a technical evaluation including reli-
ability of tests as well as ability to discriminate between 
the different AMD stages and controls. 
(2) Longitudinal part. A 3-year longitudinal follow-
up of patients with iAMD to observe change in candidate 
endpoints over time and especially with progression from 
iAMD to late-stage AMD (GA or nAMD). The longitudi-
nal part will comprise all iAMD patients from the cross-
sectional part (n = 150) and additional 450 iAMD patients 
as well as the 50 early AMD patients (total n = 650). The 
data generated will be used to assess the predictive power 
of endpoint candidates for progression of vision impair-
ment in iAMD and progression to late AMD.
Inclusion and allocation to study groups will be based 
on the disease stage of both eyes (Table 1). Late-stage 
AMD will be defined as follows: GA will be defined as a 
retinal area with a severely reduced signal by fundus au-
tofluorescence and with a minimum area size of 0.1 mm2 
as quantified by RegionFinder software, correlating to 
loss of the outer nuclear layer and the occurrence of cho-
roidal signal enhancement on spectral-domain optical 
coherence tomography (SD-OCT) and spatially confined 
to either complete or incomplete depigmentation or oth-
er AMD typical changes (e.g., hyperpigmentation, crys-
talline deposits) on color fundus photography (CFP), 
provided any hemorrhages or exudates are absent. Final-
ly, no leakage must be present on fluorescence angiogram 
(FA) (examination at the discretion of the investigator). 
CNV will be defined based on CFP, SD-OCT, and/or FA 
(optional). Evidence of CNV must include at least 2 of the 
following within a radius of 3,000 μm of the fovea: (1) se-
Table 1. Definitions of AMD disease stages used in MACUSTAR
Subjects 
planned
AMD category Morphological criteria according to the 
Beckmann classification
As applied in the MACUSTAR clinical study
50 No apparent aging 
changes (no AMD) 
No drusen and no AMD pigmentary 
abnormalitiesa
No or normal aging changes (in both eyes) are  
the same category in the MACUSTAR study,  
age-matchedNormal aging 
changes (no AMD)
Only drupelets (small drusen ≤63 μm) and 
no AMD pigmentary abnormalities*
50 Early AMD (both 
eyes)
Medium drusen >63 and ≤125 μm and 
no AMD pigmentary abnormalitiesa
Bilateral early AMD, i.e. both eyes
600 Intermediate AMD 
(iAMD)
Large drusen >125 μm and/or
any AMD pigmentary abnormalitiesa
Bilateral iAMD or iAMD in the study eye and 
extrafoveal GA in the fellow eye (maximum lesion 
size 1.25 mm2)
50 Late AMD Neovascular AMD and/or
any geographic atrophy
Bilateral GA, bilateral neovascular AMD, or 
neovascular AMD in one eye and GA in the other
AMD, age-related macular degeneration. a Any definite hyper- or hypopigmentary abnormalities associated with medium or large 
drusen but not associated with known disease entities [10].
MACUSTAR – Clinical Validation of 
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Table 2. Inclusion and exclusion criteria for the MACUSTAR clinical study
Inclusion criteria
General 1 Male and female subjects
2 Aged 55–85 years at baseline
3 Able and willing to provide written informed consent and to comply with the study protocol visits and 
assessments; in case the subject is physically incapable of signing the ICF, this can be provided by a legally 
acceptable representative of the subject or impartial witness
No AMD 1 No signs of early, intermediate, or late AMD in both eyes
Early AMD 1 Subjects with medium drusen >63 and ≤125 μm and no AMD pigmentary abnormalities in both eyes and 
no signs of intermediate or late AMD
Intermediate AMD 1 Study eye must have iAMD and
2 The fellow eye must have iAMD and/or, in addition, extrafoveal GA (no atrophy within the central 
ETDRS subfield), maximum total GA size is 1.25 mm2 
Definition of iAMD: large drusen >125 µm and/or any AMD pigmentary abnormalities that are definite 
hyper- or hypopigmentary abnormalities associated with medium or large drusen but not associated with 
other known disease entities; if both eyes are eligible for the study based on inclusion criteria, the eye with 
better visual acuity (i.e., on BCVA) will be selected as the study eye as this will improve reliability of 
functional testing and quality of image acquisition and thus improve sensitivity to detect change over 
time; In cases in which both eyes have the same visual acuity, the study eye will be selected at random by 
the investigator
3 ETDRS letter chart BCVA in the study eye not worse than 72 letters (approximately 20/40 Snellen VA 
equivalent)
Late AMD 1 Subjects with bilateral GA, bilateral nAMD or nAMD in one eye and GA in the other
2 BCVA between 20/80 and 20/200 in study eye
Exclusion criteria
General 1 Media opacity or eye movement disorder (nystagmus) that interferes with retinal imaging data quality in 
the opinion of the investigator
2 Severe ptosis, extraocular motility restriction or head tremor preventing adequate fundus visualization in 
the opinion of the investigator
3 Any signs of nAMD or GA (does not apply to the late AMD group)
4 Any concurrent intraocular condition in the study eye (e.g., glaucoma or cataract) that, in the opinion of 
the investigator would either require surgical intervention during the study to prevent or treat visual loss 
that might result from that condition or affect interpretation of study results
5 Severe nonproliferative diabetic retinopathy, or proliferative diabetic retinopathy
6 Any diabetic macular edema or macular disease
7 Ocular disorders in the study eye (i.e., preretinal membrane) at the time of enrolment that may confound 
interpretation of study results and compromise visual acuity
8 Diagnosis of uncontrolled glaucoma with intraocular pressure of >30 mm Hg (despite current 
pharmacological or nonpharmacological treatment)
9 Known systemic illness which in the opinion of the investigator will prevent from actively participating in 
the study
10 Concomitant treatment for AMD in either eye (concomitant use of vitamins/supplements is not excluded; 
does not apply to the late AMD group)
11 Any periocular or intravitreal injections (IVT) in either eye (does not apply to the late AMD group)
12 Participation in any other interventional trial
13 Obvious retinal changes due to causes other than AMD (e.g., evidenced by an existing diagnosis of 
monogenetic macular dystrophies, Stargardt disease, cone rod dystrophy, or toxic maculopathies)
14 Any history of allergies to fluorescein
15 Cognitive impaired subjects, illiterate, and subjects who do not speak the national language
No AMD 1 Early to late AMD (following Beckman classification) in any eye
Early AMD 1 Intermediate or late AMD (following Beckman classification) in any eye
Intermediate AMD 1 Any GA in the study eye
2 Any extrafoveal GA larger than 1.25 mm2 (as defined above) in the fellow eye
Late AMD (All general exclusion criteria only)
Finger et al.Ophthalmologica6
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rous detachment of the sensory retina; (2) subretinal/ ret-
inal hemorrhage; (3) pigment epithelial detachment (ex-
cluding drusenoid pigment epithelial detachment); (4) 
fibrous tissue; (5) hard exudates; (6) disciform scar. 
Through the use of multimodal functional testing and 
imaging, subclinical stages of late AMD are likely to be 
identified during the study. As the MACUSTAR study 
(amongst others) aims at finding early markers of disease 
progression in patients with iAMD, results indicating 
possible progression will not replace the diagnostic crite-
ria of late-stage AMD described above. 
Note that the Beckman classification of AMD defines 
disease stage per the individual eye. In MACUSTAR, the 
same disease stage in both eyes of one subject is generally 
required. Two exceptions have been defined in the study 
protocol. First, small GA areas up to a maximum lesion 
size of 1.25 mm2 may be present in the fellow eye for the 
iAMD group, provided extrafoveal location is present. 
Second, no distinction between GA and neovascular 
AMD is applied in the late AMD group. 
For each patient, one eye is selected as study eye. If 
both eyes are eligible for the study based on inclusion cri-
teria (Table 2), the eye with better BCVA will be selected 
as the study eye. In cases in which both eyes have the same 
visual acuity, the study eye will be selected by the investi-
gator. Before enrollment, morphological inclusion and 
exclusion criteria need to be confirmed by the central 
reading center. 
As the examinations per visit are comprehensive, pa-
tient acceptance was assessed accurately beforehand. The 
complete visit duration was 3 to 4 h, which was not re-
ported to be inacceptable by any patients.
The MACUSTAR clinical study will be carried out in 
20 clinical sites (see online suppl. material) of the Euro-
pean Vision Clinical Research Network (EVICR.net), a 
dedicated network for multinational ophthalmology clin-
ical research. These clinical sites will identify subjects 
with AMD as well as controls mainly from regular oph-
thalmologic consultations, inform them about the study 
and screen those subjects interested in participating.
Sample Size
The cross-sectional part of the MACUSTAR clinical 
study will recruit 50 normal, 50 early AMD, 50 late AMD, 
and 150 iAMD patients across the three age categories 55–
64 years, 65–74 years, and ≥75 years (age limit 85 years at 
baseline). Although limited information is available on 
test-retest reliability and on the distributions of the out-
come measures within the four disease stages (no disease, 
early, intermediate, and late AMD), these numbers are 
justified by the following considerations [13]: (a) If one 
considers a continuous outcome measure and assumes a 
moderately high effect size (Cohen’s f = 0.34) in one-way 
analysis of variance, 50 patients per disease stage will be 
sufficient to detect mean differences between the four 
groups with 80% power at the 5% alpha level of signifi-
cance (overall F-test). In addition, the planned sample size 
will be sufficient to detect differences with 80% power at 
the Bonferroni-Holm-corrected 5% alpha level in post hoc 
tests comparing the mean outcome in the iAMD group to 
the respective means in the other patient groups. (b) The 
analysis of the test-retest reliability of continuous out-
comes in the iAMD patient group will be based on intra-
class correlation coefficients (ICCs). Assuming that there 
are two ratings per patient and that the minimum accept-
able ICC is 0.75, based on available data for microperim-
etry, 150 iAMD patients will be sufficient to reject the null 
hypothesis “ICC ≤0.75” for true values of ICC > 0.85 with 
80% power at the one-sided 2.5% alpha level [14, 15]. 
For the longitudinal part of the MACUSTAR clinical 
study, a total of 600 iAMD patients across the age catego-
ries mentioned above will be recruited and followed up 
6-monthly over 3 years. Although currently available data 
on the change in structural, functional or patient-related 
outcome measures preceding progression from iAMD to 
late AMD are insufficient to accurately calculate a sample 
size, this number is justified by the following consider-
ations: using available data on microperimetric changes 
in retinal sensitivity [10], which is one of the key candi-
date methodologies for functional biomarkers in iAMD, 
and assuming constant rates of change (dB/y), the aver-
age 3-year longitudinal changes in microperimetry were 
estimated to be –1.26 dB in eyes that show morphological 
AMD progression in terms of changes in drusen or pig-
mentation according to two experienced graders and 
–0.93 dB in eyes that do not. Due to a lack of data in the 
literature correlating pointwise sensitivity from micrope-
rimetry with progression of AMD, the outlined reference 
group was chosen as a substitute. The subjects progress-
ing morphologically are assumed to have a noticeably in-
creased risk for progression of the disease to late AMD. 
Based on data from a recent iAMD cohort that has been 
followed up for 3 years [16], approximately 23% of iAMD 
patients are expected to progress to late AMD within the 
3-year study period. Assuming normally distributed 
change rates and a dropout rate of 20% after 3 years, an 
estimated number of n = 600 patients will be sufficient to 
detect a [(–1.26) – (–0.93)] dB = –0.33 dB difference in 
microperimetry change rates between possible progres-
sors and nonprogressors (alpha = 5%). This estimation is 
MACUSTAR – Clinical Validation of 
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based upon the very limited longitudinal data regarding 
mesopic microperimetry in individuals with AMD. At 
the time the study was planned, no relevant studies on 
scotopic microperimetry in AMD were available. Power 
will be > 80% if the standard deviations of the change rates 
are smaller than the absolute values of the mean change 
rates (i.e., |mean/SD| > 1, an assumption justified by the 
results by Wu et al. [10]). The sample size of 600 iAMD 
patients will be sufficient to develop a prediction model 
for progression to late AMD (combining 3-year changes 
in microperimetry, dark adaption, low luminance acuity 
[LLA] and other measures) and to estimate true- and 
false-positive rates at a high precision. For example, since 
the expected number of late AMD events will be approx-
imately equal to 110 (assuming a dropout rate of 20% af-
ter 3 years and a progression rate of 23%), there will be 
approximately 25 events per variable in a four-variable 
prediction model in tenfold cross-validation and more 
than 20 events per variable in fivefold cross-validation 
[17]. Furthermore, assuming that the sensitivity and 
specificity rates of the prediction model range between 95 
and 99%, a sample size of n = 600 patients will result in 
95% confidence intervals for tenfold-cross-validated sen-
sitivities and specificities that are narrower than 0.11 and 
that have lower bounds above 0.89 [18]. 
To avoid low data quality and missing data, the elec-
tronic case report form has built in data checks, avoids 
ambiguity, and has a user-friendly design. The central 
reading center, one of the project partners, the Associa-
tion for Innovation and Biomedical Research on Light 
and Image (AIBILI), and clinical data monitors will per-
form ongoing data quality checks. 
Outcome Measures
Based on available literature and expert consensus as 
outlined above, the following outcomes measures will be 
integrated as candidates for clinical validation in iAMD 
into the MACUSTAR clinical study, a natural history 
study in iAMD for validation of clinical endpoints.
Functional Outcome Measures
Patients with iAMD frequently report difficulties in 
dim illumination (e.g., reading menus in restaurants) and 
in low contrast situations (e.g., navigating staircases, driv-
ing at night, driving through tunnels, etc.) [11, 19, 20]. 
Against this background, a set of functional vision tests 
conducted at low luminance will be validated to reliably 
cover the functional impairment in iAMD. Also, the 
course of these functional outcomes during progression 
to late stage AMD will be assessed. 
For all functional tests, we will assess functional chang-
es meaningful to the participant – referred to as minimal-
ly important difference (MID). Combining functional test 
results with patient-related outcome (PRO) assessments 
will allow us to capture MIDs for all functional tests by 
systematically assessing whether a clinically assessed 
change in function translates to a patient-reported change 
in functioning, as well as patient preferences (i.e., utility).
The following tests of visual function will be performed 
in both parts of the MACUSTAR clinical study (cross-
sectional and longitudinal) in addition to standard high-
contrast BCVA. 
(1) Fundus-controlled perimetry (microperimetry). Ru-
bin and coworkers [21] developed the first scotopic micro-
perimeter by adding neutral density filters to a commercial 
photopic instrument (Nidek MP1, Nidek Technologies, 
Italy) to reduce the luminance of background and test 
stimuli. In a recent, exploratory study of 20 patients with 
advanced AMD, they found scotopic microperimetry to be 
the best predictor of patient-reported difficulties under 
low light as measured by the Low Luminance Question-
naire (LLQ). In patients with iAMD, localized scotopic 
dysfunction is more pronounced compared to mesopic 
dysfunction in areas with reticular drusen, a risk factor for 
AMD progression [22]. Preparatory assessments showed 
that where early scotopic microperimeters had problems 
with testing accuracy, speed, and acceptability to patients, 
the scotopic MAIA (S-MAIA, Centervue, Italy) is easier to 
operate, with less operator-induced variability. Further, it 
appears to be less affected by ceiling and floor effects due 
to its extended range for both mesopic and scotopic testing 
[23, 24]. Therefore, the MACUSTAR consortium will use 
the S-MAIA microperimeter for this project. As persons 
with AMD are known to adapt to reduced light levels more 
slowly than people without the condition [25], preliminary 
data are currently collected to determine the optimal dura-
tion of dark adaptation for the mesopic and scotopic tests 
in this patient cohort. The aim is to ensure that all partici-
pants are at a steady state level of adaptation when the mi-
croperimetry tests are conducted. 
(2) LLA. The Salisbury Eye Evaluation (SEE) is a sim-
ple test of vision at low luminance [26]. All that was re-
quired was a pair of dark sunshades which reduce lumi-
nance by 1.4 log units, i.e. a factor of 25. This moves the 
test into the mesopic range. Using a neutral density filter 
that reduced the luminance by 2 log units, Sunness et al. 
[27] showed that an LLA deficit at baseline was a good 
predictor of GA progression. Finger and colleagues [11] 
found that the LLA deficit predicts patient-reported dif-
ficulties with night vision in iAMD. 
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(3) Moorfields Acuity Test (MAT; Vanishing Opto-
types). Shah et al. [28] have developed a new set of opto-
types for measuring visual acuity that consist of pseudo 
high-pass letters. The authors have demonstrated that the 
new optotypes have better test-retest variability than tra-
ditional optotypes, and recent evidence suggests that they 
are more sensitive to vision loss in early AMD to iAMD 
[29]. 
(4) Dark adaptation. Impaired dark adaptation in 
AMD patients results in patient-reported difficulties 
with night vision, especially when moving from high to 
low ambient illumination [25]. In a study of 325 normal 
participants, abnormal dark adaptation at baseline was 
a predictor of AMD onset over 3 years [30]. Longitudi-
nal data from a small number of eyes with different stag-
es of AMD also suggest that disease progression is re-
flected in advancing delays in rod-mediated adaptation 
[9]. Traditional dark adaptation measurement is very 
lengthy as it is measured until absolute threshold is 
reached. A faster alternative is to monitor dark adapta-
tion only until it reaches a criterion threshold. A recent-
ly developed and introduced commercial instrument, 
the AdaptDx (Maculogix, USA), will be used in the MA-
CUSTAR clinical study to measure the so-called rod in-
tercept time (time to reach a threshold located within 
the second component of rod recovery). Adaptation is 
assessed for up to 20 min at a single location just outside 
the macula [31]. The standard diagnostic protocol for 
the device is based on a pass/fail criterion, where an ad-
aptation time falling outside of a specific window is con-
sidered to be “abnormal” [31]. For a longitudinal study, 
this is an insufficiently precise outcome. Thus, we will 
determine the optimal bleach intensity and retinal loca-
tion for testing people with iAMD. The aim of this stan-
dardization process is to select testing parameters, which 
will allow an actual value for rod intercept time to be 
obtained for the majority of participants with iAMD 
within a 20-min recording period. In addition, the 
AdaptDx will be used to measure Absolute Rod Thresh-
old, the minimum intensity of light detectable when ful-
ly dark adapted. 
(5) Contrast sensitivity (CS). A number of small studies 
have evaluated the effect of AMD on CS to various spatial 
frequencies, and evidence suggests that a mid-high spatial 
frequency deficit is present [32]. However, there is a pau-
city of data evaluating the ability of CS to predict and 
monitor disease progression in individuals with iAMD. 
Given the strong relationship between reduced CS and 
self-reported problems performing activities of daily liv-
ing [33], an assessment of CS has the potential to provide 
a clinically meaningful outcome measure, which is why a 
classic chart-based test of CS (Pelli Robson) will be in-
cluded.
(6) Performance-based tests (PBTs): Reading Speed and 
Navigation Performance. PBTs are standardized tests of 
everyday activities. In MACUSTAR, we will use Reading 
Speed and Navigation Performance, both performed un-
der low illumination, to help validate the outcome of 
functional assessments and PROs against activities of dai-
ly life (ADL). For the reading PBT, we will use the Inter-
national Reading Speed Texts (IReST) developed by 
members of this consortium, translated and standardized 
for all major European languages [34]. 
Navigational PBTs will utilize two unique facilities – 
the Pedestrian Accessibility and Mobility Laboratory 
(PAMELA) in London and Streetscape in Paris, Fonda-
tion Voir et Entendre – FVE. Both facilities allow stan-
dardized illumination levels that can simulate walking 
through a residential street scene at night and are the only 
such facilities available in Europe. Conditions are compa-
rable at both facilities, i.e. the same levels of illumination, 
etc. Navigational performance will be assessed in the 
cross-sectional part of the study.
Structural Outcomes Measures
To date, the state-of-the-art in retinal imaging of non-
neovascular, atrophic late AMD progression is based on 
multimodal retinal imaging which combines several im-
aging approaches. These include:
• CFP
• SD-OCT more recently supplemented by OCT-angi-
ography
• Blue and green confocal scanning laser ophthalmos-
copy (cSLO) fundus autofluorescence
• Near-infrared cSLO reflectance imaging.
Image data acquisition will be carried out according to 
standard operational procedures, including electronic 
data transmission to the reading center and certification 
of study-site technicians and photographers. Trained and 
independent readers will independently and systemati-
cally analyze imaging data according to predefined grad-
ing parameter. This also includes final confirmation of 
development of late AMD in any eye during the study (for 
specific criteria see Table 1).
A large number of previous and current clinical stud-
ies assessing AMD progression still rely on CFP. How-
ever, this is not sufficiently sensitive or specific for struc-
tural assessment of the complex retinal abnormalities in 
iAMD. An optimized combination of these existing im-
aging technologies has not been determined and clini-
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cally validated but will be the basis for an in-depth assess-
ment of structural abnormalities and their progression in 
iAMD. 
As the latest technological advancements provide con-
tinuously growing number of imaging modalities, retinal 
imaging produces an increasing amount of data. These 
data provide unique high-resolution structural disease 
information and allow us to potentially measure an array 
of relevant imaging biomarkers. However, the current 
state-of-the-art in retinal imaging analysis uses visual in-
spection to extract these biomarkers. With stringent ap-
plication of multimodal imaging approaches, there is a 
large volume of multimodal images to be analyzed. Hu-
mans are unable to efficiently exploit all the acquired in-
formation, and commonly only a limited number of im-
aging biomarkers are extracted. Moreover, accuracy and 
reliability of measurements vary within and between 
graders, leading to imprecise biomarker assessment and 
reduced prognostic power. 
Automatic and semiautomatic computerized quantifi-
cation of imaging biomarkers could substantially add to 
efficient exploitation of multimodal image information, 
obtaining faster, more accurate, and more reproducible 
measurements. Developed algorithms will be implement-
ed in the central reading center for a validation against the 
current gold standard of manual grading. Currently avail-
able algorithms have several limitations. The most com-
monly available algorithms measure the thickness of the 
retina or sublayers within the retina, but these may be 
inaccurate in the presence of disease [35], and are not well 
correlated to functional deficits. Sanchez et al. [36] have 
been using deep learning approaches to improve the ro-
bustness of layer segmentations, which may help with 
both problems. Other features available commercially in-
clude measures of elevation of the RPE, which may be 
correlated to likelihood of progression [35]. It will be use-
ful to see if these are also correlated to functional deficits. 
There are numerous other morphological features that 
are known to be associated with severity of disease or risk 
of progression such as reticular pseudodrusen, but these 
are not yet quantified by any commercial software. Sán-
chez et al. [36] and others [37–41] have previously de-
signed computer-based algorithms for the automatic ex-
traction of several morphological biomarkers based on 
one or several imaging modalities. Although promising, 
the performance of these algorithms needs to be further 
improved to detect small, characteristic changes in iAMD 
that can be correlated to function, patient reports, or risk 
of progression if they were to be utilized in future CTs. 
Also, the functional relevance of any of the structural can-
didate biomarkers needs to be validated against function-
al changes to support their clinical relevance for future 
clinical endpoints.
Patient-Reported Outcome Measures
As highlighted above, persons with iAMD often report 
difficulties with contrast and low luminance. We found 
that self-reported night vision symptoms are associated 
with low luminance deficit [11] and the degree of self-
reported problems with night vision could be shown to be 
predictive of disease progression from early to late AMD 
(especially GA) as well as a loss of BCVA ≥3 lines over a 
period of 6 years [42, 43]. 
However, most currently available vision-related PRO 
measures (PROMs) are focused on assessing the impact 
of visual loss, and almost always have a ceiling effect (i.e., 
patients report no problems or tasks are too easy) in per-
sons with good BCVA as is the case in iAMD. Thus, they 
are poorly targeted to the study population, and better 
targeted PROMs need to be developed. While there are 
instruments that measure different aspects of visual func-
tioning and vision-related quality of life including subjec-
tive dysfunction in low luminance (e.g., Low Luminance 
Questionnaire, NEI Visual Functioning Questionnaire 
25), no vision-related PRO has been accepted by regula-
tory authorities as a clinical endpoint since recent guide-
lines for development of such tools have not been system-
atically followed. To allow drug development, which will 
target the low-luminance and low-contrast visual impair-
ment of patients with iAMD, a novel PRO needs to be 
developed in accordance with existing guidelines from 
regulatory authorities. Results from this new PRO will 
also need to be correlated with functional endpoints, and 
PBT to understand the relationship between measures of 
function and patient report.
In order to allow for economic assessments of vision 
treatments alongside iAMD CTs, a utility measure sensi-
tive to changes in vision is needed. Conventional generic 
utility measures such as the EQ-5D have been shown to 
be inappropriate in vision [44]. The added value of a 
number of recent developments in the field including the 
EQ-5D vision “bolt-on” that provides an extra vision di-
mension [45] and Vision Function Questionnaire Utility 
Index (VFQ-UI) [46] remains unclear. Thus, in order to 
allow for optimal utility capture in iAMD CTs a health 
state utility index will be developed to allow utility values 
to be generated alongside the collection of PRO data to 
ensure that future CTs generate data on patient-relevant 
benefits that can be utilized in cost-effectiveness analyses 
by HTA and reimbursement authorities.
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Statistical Analysis
Since the aim of the cross-sectional part of the clinical 
study is to evaluate the sensitivity, repeatability, and dis-
criminant ability of the candidate endpoints described 
above, statistical analysis of these endpoints will be based 
on methods for measuring agreement and for analyzing 
differences between the disease groups. This will be done 
by computing intraclass correlation coefficients (ICCs) 
with 95% confidence intervals for continuous outcomes 
and Fleiss’ kappa coefficients with 95% confidence inter-
vals for ordinal outcomes. Graphical analysis of agree-
ment will be performed using scatterplots and Bland-Alt-
man plots for continuous outcomes, and heat maps for 
ordinal outcomes.
In the longitudinal part of the study, multivariable 
regression and discrete time-to-event analyses will be 
conducted in order to assess the associations of changes 
in functional, structural and PRO measures with pro-
gression to late AMD. Both, progressions to nAMD and 
to GA will be considered as progression events. Based on 
these exploratory models, we will develop a predictive 
model using the rate of change in one or several func-
tional measures, structural measures and/or PRO mea-
sures to predict progression to late-stage AMD. For this 
analysis, rates of change over time will be established for 
all functional, structural, and PRO measures, and “points 
of no return” will be assessed for structural measures. 
This will be done for (a) all progression events to late-
stage AMD and for (b) nAMD and GA separately. Re-
sults will be compared to identify biomarkers suggested 
to be specific for progression to one or the other late-
stage AMD type. For predictive modelling, we will con-
sider logistic regression, but will also investigate the use 
of statistical learning methods such as random forests, 
artificial neural networks, and support vector machines. 
Predictive models will be derived and evaluated by re-
peated k-fold cross-validation [47]. Accuracy of the 
models will be evaluated on the test datasets using per-
formance measures such as AUC and partial AUC [47]. 
Structural-functional correlations such as the correla-
tion of localized retinal changes to quantitative results 
of fundus-controlled perimetry will be performed. Re-
porting of the various prediction models will follow the 
principles and guidelines of the TRIPOD Statement 
[48]. 
A combination of functional information from micro-
perimetry measurements and structural information 
from multimodal retinal imaging may further improve 
the performance of these two individual biomarkers. 
These kinds of analyses have not been performed before 
in patients with iAMD. It is likely that clinically signifi-
cant deterioration in functional measures may be partial-
ly masked by measurement imprecision resulting in lim-
itation in the ability to identify disease progression by the 
functional measurement alone. In this situation, infor-
mation on novel or progressive structural deficits from 
multimodal retinal imaging could improve the perfor-
mance of the biomarkers. Analysis of structural parame-
ter outcomes in the same model as outcome of the func-
tional measures would mitigate measurement variability 
and increase the signal-to-noise ratio. An improved sig-
nal-to-noise ratio would allow disease deterioration to be 
identified, therefore increasing the power of a CT to iden-
tify treatment effects. Modelling of joint outcomes has 
shown potential in other diseases [49–51]. 
Simply put, each person would have a functional 
“chance” and a structural “chance” of changing; then, we 
combine these probabilities in a Bayesian framework. 
Crabb and colleagues [52] have successfully done this in 
people with ocular hypertension, when trying to predict 
progression to glaucoma, using measures from standard 
automated perimetry and neuroretinal rim area imaging. 
This particular prescription simply relies on combina-
tions of single summary measures on rate of change from 
the two measurement modalities, combining measure-
ments in “higher dimensions” retaining “layers” of infor-
mation from each measurement – pixel/voxel intensity in 
images and single visual field points [53]. The same could 
easily be applied to regional changes from microperime-
try and specific areas of change on imaging, taking advan-
tage of modern statistical feature extraction methods 
[54]. 
Conclusions
Herein, we outline the protocol development of the 
MACUSTAR clinical study which will establish a toolbox 
of functional, structural, and patient-reported outcome 
measures for use in future iAMD CTs. Likely a combina-
tion of multiple outcome measures will be used to assess 
progression and may serve as a surrogate endpoint for 
progression to late AMD. As the functional deficit in 
iAMD is most pronounced under low luminance and low 
contrast conditions, this is what we will explore in MA-
CUSTAR.
Strengths of our protocol development are integration 
of available data, comprehensive expertise including bio-
statisticians, as well as feedback from all relevant regula-
tors and HTA bodies. Limitations are the lack of pilot data 
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for the overall protocol at this stage, a possible selection 
bias (such as sampling bias due to the nonrandom sample 
out of subjects with iAMD, attrition bias), as well as the 
uncertainty around the sample size planning given the 
lack of necessary data around functional changes preced-
ing progression from iAMD to late AMD. Considering 
this, our current sample size assessments are the best pos-
sible to date.
In conclusion, novel outcome measures are needed for 
iAMD CTs as conventional high-luminance, high-con-
trast functional testing, or existing PROMs are unlikely to 
detect functional loss or patient-relevant impact of the 
disease and thus cannot be used in future CTs for iAMD. 
A combination of candidate outcome measures assessing 
function under low-luminance and low-contrast condi-
tions with structural outcomes which allow for a topo-
graphical correlation may improve precision of the mea-
surement and should be explored.
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